69 related articles for article (PubMed ID: 20486472)
1. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
Uckun FM; Dibirdik I; Qazi S; Yiv S
Arzneimittelforschung; 2010; 60(4):210-7. PubMed ID: 20486472
[TBL] [Abstract][Full Text] [Related]
2. Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.
Uckun FM; Dibirdik I; Qazi S
Arzneimittelforschung; 2010; 60(4):218-25. PubMed ID: 20486473
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.
Linwong W; Hirasawa N; Aoyama S; Hamada H; Saito T; Ohuchi K
Br J Pharmacol; 2005 Jul; 145(6):818-28. PubMed ID: 15852029
[TBL] [Abstract][Full Text] [Related]
5. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
Uckun FM; Ek O; Liu XP; Chen CL
Clin Cancer Res; 1999 Oct; 5(10):2954-62. PubMed ID: 10537365
[TBL] [Abstract][Full Text] [Related]
6. [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131].
Mitiushova EV; Aksenov ND; Marakhova II
Tsitologiia; 2010; 52(2):184-90. PubMed ID: 20352702
[TBL] [Abstract][Full Text] [Related]
7. Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases.
Sahin K; Yabas M; Orhan C; Tuzcu M; Sahin TK; Ozercan IH; Qazi S; Uckun FM
Expert Opin Ther Targets; 2020 Apr; 24(4):379-387. PubMed ID: 32106727
[No Abstract] [Full Text] [Related]
8. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Uckun FM; Roers BA; Waurzyniak B; Liu XP; Cetkovic-Cvrlje M
Blood; 2002 Jun; 99(11):4192-9. PubMed ID: 12010825
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in JAK3 kinase inhibitors.
Sudbeck EA; Uckun FM
IDrugs; 1999 Oct; 2(10):1026-30. PubMed ID: 16118711
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-alpha.
Sareila O; Korhonen R; Kärpänniemi O; Nieminen R; Kankaanranta H; Moilanen E
Int Immunopharmacol; 2008 Jan; 8(1):100-8. PubMed ID: 18068105
[TBL] [Abstract][Full Text] [Related]
11. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation.
Tibbles HE; Vassilev A; Wendorf H; Schonhoff D; Zhu D; Lorenz D; Waurzyniak B; Liu XP; Uckun FM
J Biol Chem; 2001 May; 276(21):17815-22. PubMed ID: 11278899
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131).
Malavija R; Chen CL; Liu XP; Uckun FM
Am J Ther; 2001; 8(1):35-9. PubMed ID: 11304656
[TBL] [Abstract][Full Text] [Related]
13. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.
Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Cho S; Kim JS; Kim JH; Choe JH; Nam SJ; Lee JE; Yang JH
Cell Signal; 2009 Jun; 21(6):892-8. PubMed ID: 19385051
[TBL] [Abstract][Full Text] [Related]
14. Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Uckun FM; Erbeck D; Qazi S; Venkatachalam T; Tibbles HE; Vassilev A
Arzneimittelforschung; 2007; 57(6):320-9. PubMed ID: 17688077
[TBL] [Abstract][Full Text] [Related]
15. Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131).
Chen CL; Malaviya R; Chen H; Liu XP; Uckun FM
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):205-12. PubMed ID: 10360439
[TBL] [Abstract][Full Text] [Related]
16. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).
Malaviya R; Chen CL; Navara C; Malaviya R; Liu XP; Keenan M; Waurzyniak B; Uckun FM
J Pharmacol Exp Ther; 2000 Dec; 295(3):912-26. PubMed ID: 11082424
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
Narla RK; Liu XP; Klis D; Uckun FM
Clin Cancer Res; 1998 Oct; 4(10):2463-71. PubMed ID: 9796979
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
Uckun F; Dibirdik I; Sarkissian A; Qazi S
Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
[TBL] [Abstract][Full Text] [Related]
19. Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.
Cetkovic-Cvrlje M; Olson M; Ghate K
Cell Mol Immunol; 2012 Jul; 9(4):350-60. PubMed ID: 22728763
[TBL] [Abstract][Full Text] [Related]
20. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Malaviya R; Zhu D; Dibirdik I; Uckun FM
J Biol Chem; 1999 Sep; 274(38):27028-38. PubMed ID: 10480916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
